Pure Global

Adjuvant Chemoradiotherapy Followed by Zimberelimab for Locally Advanced Cervical Cancer. - Trial NCT06128460

Access comprehensive clinical trial information for NCT06128460 through Pure Global AI's free database. This Phase 2 trial is sponsored by Obstetrics & Gynecology Hospital of Fudan University and is currently Not yet recruiting. The study focuses on Cervical Cancer. Target enrollment is 24 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06128460
Phase 2
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06128460
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Adjuvant Chemoradiotherapy Followed by Zimberelimab for Locally Advanced Cervical Cancer.
Adjuvant Chemoradiotherapy Followed by Zimberelimab for Locally Advanced Cervical Cancer (IB3, IIA2) Patients

Study Focus

Cervical Cancer

Zimberelimab

Interventional

drug

Sponsor & Location

Obstetrics & Gynecology Hospital of Fudan University

Timeline & Enrollment

Phase 2

Dec 01, 2023

Dec 01, 2029

24 participants

Primary Outcome

changes in tumor-related biomarkers

Summary

Locally advanced cervical cancer (stage IB3, IIA2) patients with postoperative risk factors
 need better treatment. We initiated a clinical study to explore the effectiveness of adjuvant
 chemoradiotherapy followed by Zimberelimab for these patients.

ICD-10 Classifications

Severe cervical dysplasia, not elsewhere classified
Mild cervical dysplasia
Moderate cervical dysplasia
Carcinoma in situ: Cervix, unspecified
Cervical root disorders, not elsewhere classified

Data Source

ClinicalTrials.gov

NCT06128460

Non-Device Trial